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a  b  s  t  r  a  c  t
Aim  and  Background:  Propolis  has  been  used  for the management  of  oral mucositis  in a  number  of  studies.
Due  to lack  of sufficient  evidence  especially  in  radiotherapy  induced  oral  mucositis,  the  present  study
was  designed  to  evaluate  the  efficacy  and  safety  of  propolis  mouthwash  in oral  mucositis  and  dysphagia
in  patients  undergoing  head  and  neck  radiotherapy.
Materials  and  methods:  This  study  was  a prospective,  randomised,  double-blind,  placebo-controlled  trial.
The patients  randomly  divided  into  two  groups  receiving  either  the propolis  or  the  placebo  mouthwash.
Patients  were  advised  to  rinse  their  mouth  with  15 mL  three  times  daily  for  four  weeks.  Severity  of
mucositis  and  dysphagia  were  evaluated  by  the  National  Cancer  Institute  Common  Toxicity  Criteria  (NCI-
CTC) and  Common  Terminology  Criteria  for  Adverse  Events  (CTCAE),  respectively.
Results: Thirty  patients  completed  the  study.  Each  group  consisted  of  15  patients.  Although,  there  is not
any  significant  difference  between  two groups  in  the  first  week  of  radiotherapy,  a  significant  difference
was  seen  in  the  second,  the  third  and  the fourth  week  (p  =  0.03,  0.02, 0.02,  respectively).  Dysphagia
reported  as  a mild  score  in  the propolis  group  only  in  the  fourth  week  which  is  significant  compared  with
the  placebo  group  (p  = 0.01).  There  is  not  any  serious  adverse  effect  related  to  propolis  or  placebo  during
the study.
Conclusion:  It seems  that  propolis  mouthwash  is an  effective  and  safe  medication  for  alleviation  of  oral
mucositis  and  dysphagia  in patients  under  head  and  neck  radiotherapy.










Oral Mucositis (OM) is an erythematous and painful ulcerative
lesion in the oral cavity of patients with cancer who are treated with
radiotherapy, chemotherapy or both.1 It is also one of the most
debilitating and troublesome acute side effects that profoundly
affects the quality of life. OM is associated with symptoms such
as pain, infections, dysphagia and food intake impairment, which
increases morbidity and mortality and contributes to rising health
care costs.2 Radiotherapy induces OM at daily dose of 2 Gy with
standard fractionation from the first week and reaches the peak
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1507-1367/© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights resn the third week.3 OM occurs in 10% of patients receiving adju-
ant chemotherapy, 40% of patients with induction chemotherapy
nd 80% of patients who are undergoing stem cell transplantation.
ll of patients receiving head and neck radiotherapy also suffer
rom this complication.4 Erythematous and ulcerative lesions fol-
owing OM lead to severe pain and compromise nutrition and oral
ygiene as well as increase the risk for local and systemic infection.5
he OM induced pain can be severe, which requires hospitaliza-
ion and use of parenteral opioid analgesics and, as a result, causes
he interruption of the planned cancer therapy.6 The Multinational
ssociation of Supportive Care in Cancer (MASCC) and International
ociety of Oral Oncology (ISOO) regularly assess available litera-
ure relating to pathogenesis, mechanisms, and novel therapeutic
pproaches regarding OM.  In the last version, they have that the
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restricted, inflammatory based, host innate immune response,
microbial mediated and neuro-immune signalling have been con-
sidered as the mechanism of OM induced by radiotherapy.7
Growth factors,8 anti-inflammatory agents. such as allopurinol9
and selenium,10 antimicrobial agents. such as chlorhexidine.11 and
natural products like royal jelly12 have been tried in previous stud-
ies for the management of OM.  Yet, there is still no definite and
standard way to treat or prevent this condition. Propolis also known
as “bee glue” is a multi-component hard resin found in bee hives
from certain bee species which has been employed extensively
since ancient times. Antioxidant and antimicrobial activity have
been reported frequently by Propolis in the literature.13 There are
several studies in animal model regarding a good effect of Propolis
in alleviation of radiotherapy-induced OM.14,15 Recently a system-
atic review, as a clinical practice guideline, has been published
regarding the effect of natural products such as propolis in manage-
ment of OM. It has referred to the lack of knowledge about Propolis
either topical or systemic in alleviation of OM.16
2. Aim
We  conducted a double-blind placebo-controlled trial to assess
the effect of Propolis mouthwash in the prevention of radiotherapy-
induced OM.
3. Materials and method
This is a double-blind, placebo-controlled trial conducted in two
centers of radiotherapy in Tehran, Iran. The study was  approved by
the ethical committee of the Shahid Beheshti University of Medical
Sciences with number IRSBMU.PHNM.1394.309. Also the trial was
registered in the Iranian Registry of Clinical Trials under the code
IRCT2016010225726N2. To be eligible for the study, patients with
cancer in oral cavity, nasopharynx, tongue, hypopharynx, parotid,
larynx, sub-mandibular and paranasal sinus that had undergone
radiotherapy alone or in combination with chemotherapy were
selected for the study. Mucositis usually becomes clinically evi-
dent during the second or third week of radiotherapy, so we have
decided to evaluate the results during four weeks after starting the
radiotherapy, to dose 36−40 Gy.
Radiotherapy was administered using cobalt 60 at a dose of 2 Gy
per day, five times a week. Duration of radiotherapy was  seven to
eight weeks for all patients, to total dose of 70 Gy. Patients who
needed chemotherapy in addition to radiotherapy were treated
with a constant regimen weekly cisplatin (40 mg/  m2  body sur-
face). In fact, no patients received induction chemotherapy in this
trial.
Exclusion criteria were (a) history of hypersensitivity reactions
to honey and propolis; (b) pre-diagnosed or therapy for oral dis-
eases; (c) chronic kidney disease (stage 4,5); (d) chronic liver
disease (stage 2,3); (e) receiving anticoagulants such as warfarin;
(f) patient with candidiasis; (g) history of active collagen vascular
disease; (h) white blood cell count of less than 3000/mm.3
The study was explained to the patients and informed consent
forms were received. A questionnaire was designed in which the
first part contained demographic data of patients including name,
sex, age, diagnosis, location of tumour, history of drinking alcohol,
smoking habits, oral hygiene, and plan of treatment (radiother-
apy alone or radiotherapy plus chemotherapy). The second part
was designed for the registration of grade of OM and dysphagia
before and during the 4 weeks of radiotherapy. Other preventing
modalities were applied to the patients who participated in the
study based on hospital protocol, such as advice to avoid alcohol,
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By using an online statistical computing web  program
http://www.graphpad.com/quickcalcs/randomize1.cfm), eligible
atients were registered and randomized in a 1:1 ratio to receive
ne of the two  treatments, propolis solution (case group) or placebo
olution (control group). Patients in the case group from the first
ay of radiotherapy were administered 20 mL  propolis oral solution
0.8 mg/mL, Soren Tektoos, Mashhad) three times a day. The control
roup received 20 mL  placebo solution (sterile water with allow-
ble neutral additives, Soren Tektoos, Mashhad) every 8 h. Each
ime, all the patients were instructed to brush their teeth and then
argle and rinse their mouth with 20 mL  of placebo or propolis for
 min  and swallow the solution for 4 weeks simultaneously with
he radiotherapy protocol from the first session of radiotherapy. As
e want to evaluate the effect of propolis in dyspepsia, participants
ere asked to swallow mouthwash after gargling in order to cause a
irect contact of the solution with the pharynx and upper oesoph-
gus tissue. In addition, patients who complained about pain or
ther signs attributed to severe OM were excluded from the study
nd received a more aggressive therapy, such as opioid analgesics
or OM.  Each patient was evaluated weekly for one month by the
ame clinical radiotherapist.
OM and dysphagia were assessed at baseline and every week for
ne month by using the National Cancer Institute Common Toxic-
ty Criteria (NCI-CTC) criteria and Common Terminology Criteria for
dverse Events (CTCAE), respectively. NCI-CTC scale of oral mucosi-
is is classified as 0: none, 1: erythema of the mucosa, 2: patchy
seudomembranous reaction with patches generally ≤ 1.5 cm in
iameter and non-contiguous, 3: confluent pseudomembranous
eaction with contiguous patches generally >1.5 cm in diameter, 4:
ecrosis or deep ulceration and may  include bleeding not induced
y minor trauma or abrasion.10
Dysphagia was determined by the CTCAE criteria. In this cri-
erion, dysphagia scored from 0 to 4 by the clinician based on
ymptoms, diet, and tube dependence. In Grade 0, patient is asymp-
omatic, in Grade 1 patient is symptomatic but able to eat regular
iet, in grade 2, patient is symptomatic and altered eating or swal-
owing. In grade 3, severely altered eating or swallowing appears
nd tube feeding or Total Parenteral Nutrition (TPN) or hospitaliza-
ion is indicated. Finally, in grade 4, life-threatening consequences
ccur and urgent intervention is indicated.17 If any serious adverse
vents occurred during the intervention, regarding propolis or
lacebo usage, the intervention was withheld and patient was
xcluded from the study.
Data were analysed by using SPSS software. P value less than
.05 was considered significant. Comparisons between propolis
nd placebo groups were performed using independent samples t
est, Mann–Whitney test, and Pearson’s Chi-squared test as appro-
riate. The sample size for each group was calculated according
o a previous study in which an average of OM severity 3.15 and
.90 were reported for propolis and placebo groups, respectively.
ased on the standard deviation equal to 0.7 after four weeks of
adiotherapy,18 the sample size of at least 28 patients (14 in each
roup) was estimated (using a power of %80 and at a significant
evel of %5).
. Results
Participant’s flow is summarized in Fig. 1. Thirty patients
ere enrolled and completed the study. Demographic data,
aseline oral hygiene and treatment plan of two groups are
hown in Table 1. There were no differences between the 2
roups in terms of age (p = 0.6), gender (p = 0.26), alcohol habit
p = 0.48), smoking habit (p = 0.59), opioid addiction (p = 0.99), oral
ygiene (p = 0.21), tumour location (p = 0.54), and treatment plan
p = 1).















(OR = 0.35, p = 0.003).21 In that meta-analysis, four studies out ofFig. 1. Flowc
Distribution of the severities of OM was determined separately
in the first, second, third and fourth weeks of radiotherapy on the
basis of NCI-CTC score (Fig. 2). Data analysis of NCI-CTC criteria
showed that there was no significant difference between the groups
in severity of OM in the first week (p = 0.07); however, there was a
significant difference between the two groups in severity of OM in
the second (p = 0.03). The frequency of grade 3 of OM in the third and
fourth week was 0% in the propolis group, whereas grade 3 of OM in
the third and fourth weeks were 33.33% and 13.33%, respectively, in
the placebo group. Statistical analysis showed that the difference of
OM between the two groups was significant in the third (p = 0.02)
and fourth (p = 0.02) weeks of treatment, too.
Severity of dyspaghia in the two groups is shown in Table 2.
Analysis showed that there was no significant difference between
the two groups in the first, second and third weeks of treatment
(p = 0.06, 0.24, 0.13, respectively) regarding the CTCAE score. How-
ever, in the fourth week of radiotherapy, a dominant difference
in dysphagia severity was observed where 53.33% of patients in
the placebo group and 6.66% patients in the propolis group had





nd propolis had grade 2 dysphagia in the fourth week of radio-
herapy. Statistical analysis showed that there was a significant
ifference between the two groups in dysphagia severity in that
eek (p = 0.01).
. Discussion
The mechanism of OM is complex but the control of oxidative
tress has been tried to prevent and manage OM in sev-
ral studies.19 Previous studies have reported the antimicrobial,
nti-inflammatory, and wound healing effects of propolis. Its
ntioxidant properties, having the potential for treatment and pre-
ention of oxidative stress mediated diseases.20 Kuo et al. evaluated
he efficacy and safety of propolis in cancer therapy induced OM in
 meta-analysis. They reported that the incidence of severe OM was
ignificantly lower in the propolis group than in the control groupve involved patients treated with chemotherapy alone, and only
ne study involved patients treated with radiotherapy. In general,
here are only two published studies regarding the effect of propolis
F. Dastan et al. Reports of Practical Oncology and Radiotherapy 25 (2020) 969–973
Table  1






Mean age (year) 54.2 ± 15.8 57.1 ± 14.4 0.6
Sex Female 8 4 0.26
Male  7 11
Smoking habit Never 10 10 0.59
Present smoker 4 3
Stop smoking 0 2
Past smoker 1 0
Alcohol habit Never 13 15 0.48
Present drinker 2 0
Tumour location Tongue 6 4





Paranasal sinus 2 2
Addiction No 2 1 0.99
Yes  13 14
Treatment plan Radiotherapy alone 10 9 1
Radiotherapy + chemotherapy 5 6
Oral  Hygiene Normal 6 3 0.21
Abnormal 9 12








tis in Fig. 2. Severity of oral mucosion radiotherapy-induced OM.  One of them was done by Javadzadeh
et al. published in 2015. In their study, 20 patients were selected
randomly to swish and swallow 15 mL  of propolis mouthwash or





972two groups during the study.
18M grading. In another study, Akhavan-Karbassi et al. adminis-
ered propolis or sterile water mouthwash in a double blind clinical
rial. OM in patients was  assessed at baseline and after three and
even days of treatment. They have reported that propolis mouth-
F. Dastan et al. Reports of Practical Oncology and Radiotherapy 25 (2020) 969–973
Table  2
Severity of Dysphagia in two groups.
Case (%) Control (%) P Value
Grade 0 1 2 3 0 1 2 3




Propolis for oral mucositis in patients receiving chemotherapy for head andSecond week 0.00% 66.67% 33.33% 0.00%
Third  week 0.00% 66.67% 33.33% 0.00%
Fourth week 6.66% 86.67% 6.66% 0.00%
wash may  be helpful to alleviate OM in patients with head and neck
cancer receiving radiotherapy plus chemotherapy. One limitation
of their study was the time of patient’s evaluation. Long term effi-
cacy and safety of propolis were not seen in their trial because they
performed the study only for seven days. They stated that a well
designed research was needed to confirm their findings.22
Therefore, the lack of evidence regarding the effect of propolis
in radiotherapy-induced OM leads to the present study. Age, gen-
der, oral hygiene, smoking and radiation dose have been reported
as risk factors of radiotherapy induced OM.23 In our study, two
groups were similar regarding mean age, distribution of sex, basal
oral hygiene, smoking habits and radiation dose. So, these parame-
ters could not be important as confounding factors for our results.
Like in Javadzdeh et al. study, the beneficial effect of propolis in
alleviation of OM was seen in our study. In both studies, NCI-
CTC has been used for the assessment of OM but we  determined
dysphagia severity in the patients, too. Previous studies have not
evaluated the effect of propolis on dysphagia in patients under
treatment with either chemotherapy or radiotherapy. Our results
showed that propolis had a protective effect versus placebo against
radiotherapy-induced dysphagia in the fourth week by using the
standard criteria for assessment of dysphagia (CTCAE). Also, our
results showed that propolis was effective in alleviation of OM
sooner than dysphagia. In this trial there was no drop out because of
adverse drug reactions related to propolis or placebo. It seems that
propolis solution is safe and it can be tolerated well. In summary,
this study found that oral care by propolis mouthwash for patients
undergoing head and neck radiotherapy was an effective and safe
intervention to improve oral health. The exact mechanism of propo-
lis have not been determined yet. In a reciprocal way, given the
kinetics of mucosal regimen-related injury, studies that determine
how mucosal injury is elicited by radiation may  provide fundamen-
tal knowledge about the mechanism of propolis. As mucositis is the
most frequent during the second and third weeks of radiotherapy,
we evaluated patients only for four weeks and this is a limitation of
our study. In the future it is recommended that patients are assessed
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